Literature DB >> 1724983

Hepatitis C virus RNA in blood donor sera detected by the polymerase chain reaction: comparison with supplementary hepatitis C antibody assays.

A Widell1, A S Månsson, G Sundström, B G Hansson, E Nordenfelt.   

Abstract

The low specificity of screening ELISAs for antibodies to hepatitis C virus in blood donors has called for confirmatory tests. Two types of supplementary antibody assays are available, recombinant immunoblot assays (RIBA-1 and RIBA-2) and an antibody consumption test referred to as a neutralization assay. Amplification of viral nucleic acid by the polymerase chain reaction (PCR) provides an antibody independent mode of detecting viral infection. We applied reverse transcription-double PCR to detect an HCV 5'-noncoding viral RNA sequence in serum specimens and compared PCR findings with confirmatory antibody tests. This study includes sera from 37 blood donors found positive by the Ortho anti-HCV (C100-3) ELISA out of 14,591 donations. Of the 37 positive sera, 8 were positive by RIBA-1 and 1 further by RIBA-2. Seven of the RIBA positive sera contained HCV RNA by PCR. Among the 8 indeterminate and the 21 negative donor sera by RIBA-1, no PCR positive serum was found. The 37 anti-HCV positive donor sera identified by Ortho ELISA were also tested by Abbott anti-HCV (C100-3) ELISA whereby 22 were positive. Of these 22 sera plus 1 further with ELISA OD just below cutoff, 8 were positive by the "neutralization assay," (Abbott Laboratories, North Chicago, IL, USA) and 6 of these, including the borderline serum, were PCR positive. One of the two neutralizable but PCR negative sera was RIBA positive and the other was indeterminate. However, one ELISA (Abbott Laboratories) positive (OD 1.99) serum was not neutralizable but nevertheless contained HCV RNA by PCR.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1724983     DOI: 10.1002/jmv.1890350409

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  11 in total

1.  Cloning and expression of NS3 cDNA fragment of HCV genome of Hebei isolate in E.coli.

Authors:  Fen-Lu Zhu; Hao-Ying Lu; Zhuo Li; Zhong-Tian Qi
Journal:  World J Gastroenterol       Date:  1998-04       Impact factor: 5.742

2.  Evaluation of third-generation assays for detection of anti-hepatitis C virus (HCV) antibodies and comparison with presence of HCV RNA in blood donors reactive to c100-3 antigen.

Authors:  D Lavanchy; C Mayerat; B Morel; P Schneider; C Zufferey; J J Gonvers; A Pécoud; P C Frei
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

3.  HCV transmission in family members of subjects with HCV related chronic liver disease.

Authors:  L Demelia; E Vallebona; R Poma; G Sanna; G Masia; R C Coppola
Journal:  Eur J Epidemiol       Date:  1996-02       Impact factor: 8.082

Review 4.  Mode of hepatitis C virus infection, epidemiology, and chronicity rate in the general population and risk groups.

Authors:  H L Tillmann; M P Manns
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

5.  Prevalence of HCV-RNA-positive blood donors and correlation to ELISA and RIBA status.

Authors:  M da Silva Cardoso; K Koerner; S Epple; B Kubanek
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

6.  Severe aplastic anemia associated with seronegative community-acquired hepatitis C virus infection.

Authors:  A Gruber; L Grillner; H Norder; L Magnius; M Björkholm
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

7.  Hepatitis C virus infection: its role in chronic liver diseases.

Authors:  Y Y Zhang; L S Guo; Y D Zhang; L Li; D X Yu; F H Li; Y K Wang; Z Q Yu; L J Hao; B G Hansson
Journal:  J Tongji Med Univ       Date:  1993

8.  Greater diversity of hepatitis C virus genotypes found in Hong Kong than in mainland China.

Authors:  Y Y Zhang; A S Lok; D T Chan; A Widell
Journal:  J Clin Microbiol       Date:  1995-11       Impact factor: 5.948

9.  HCV genotypes in Swedish blood donors as correlated to epidemiology, liver disease and hepatitis C virus antibody profile.

Authors:  S Shev; A Widell; U Foberg; A Frydén; S Hermodsson; G Lindh; A Lindholm; S Månsson; O Weiland; G Norkrans
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553

Review 10.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.